Home SCIENCE & GREEN TECH Future Science Editas wins Australia nod for gene editing trial (EDIT:NASDAQ)

Editas wins Australia nod for gene editing trial (EDIT:NASDAQ)

Genetic engineeering concept

PhonlamaiPhoto/iStock via Getty Images

Editorial Disclosure: This article is curated from reporting by the original publisher credited below. It was selected and published automatically under the Pune.Media Editorial Policy and is not original Pune.Media reporting.

Original Coverage & Source Attribution: seekingalpha.com

PhonlamaiPhoto/iStock via Getty Images

Editas Medicine (EDIT) traded higher on Thursday after Australian authorities cleared a Phase 1/2 trial for the company’s gene-editing therapy EDIT-401, and Wells Fargo upgraded the biotech to Overweight from Equal Weight in reaction.

In a statement, Cambridge, Massachusetts-based Editas (

Exit mobile version